Bromodomain and Extra-Terminal Domain Protein (BET) Inhibitors - Pipeline Insights, 2016

New Delhi, India, July 31, 2016 --(PR.com)-- The report provides information on the therapeutic development based on the Bromodomain and Extra-terminal Domain Protein (BET) Inhibitors across 20+ pipeline drugs and 22+ companies active in this field. DelevInsight's Report also provides the comparative analysis of Bromodomain and Extra-terminal Domain Protein (BET) Inhibitors at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also highlights the discontinued and inactive projects in pipeline.

Bromodomain and Extra-terminal Domain Protein (BET) Inhibitors - Pipeline Insights, 2016 comprehensively includes:

• In-depth analysis of the pipeline assets across this mechanism of action.
• Insights on 20+ products with 22+ companies which are active in this field.
• R&D activities and technologies used along with the pipeline molecules in development.
• Information related to collaborations, in-licensing and out-licensing deals.
• Stages of development of pipeline molecules.
• Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.
• Highlights the discontinued and inactive projects in pipeline.

Bromodomain and Extra-terminal Domain Protein (BET) Inhibitors - Pipeline Insights, 2016 Report envisage Pipeline Intelligence by identifying the key players along with their potential pipeline molecule. Therefore DelveInsight's report on Bromodomain and Extra-terminal Domain Protein (BET) Inhibitors helps to optimize portfolio by creating effective counter-strategies to gain competitive and therapeutic advantage in global Pharma market. In addition, it assesses the major market drivers and barriers in development of Pipeline molecules which helps to understand market for collaborations and licensing deals.

DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 3,750 as a Global/Enterprise License.

For more information on Pipeline Insight Reports, email at info@delveInsight.com

About Us:

DelveInsight is a leading Business Consulting and Market Research Firm. We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.